Loading...
XTAI
4108
Market cap88mUSD
Jul 14, Last price  
13.00TWD
1D
-0.76%
1Q
-4.41%
Jan 2017
-57.45%
IPO
-68.00%
Name

Phytohealth Corp

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
16.81
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1.82%
Rev. gr., 5y
9.97%
Revenues
154m
-5.49%
99,193,000107,904,000155,092,000177,711,000144,988,00090,732,00020,978,00025,021,00053,996,000107,483,00095,485,00091,810,000168,936,000135,465,000162,489,000153,562,000
Net income
-74m
L+56.00%
-267,053,000-215,119,000-170,071,000-103,794,000-182,964,000-321,702,000-203,500,000-194,516,000-206,349,000-182,476,000-170,927,000-118,655,000-78,021,000-115,035,000-47,117,000-73,501,000
CFO
-50m
L-8.47%
-107,148,000-193,063,000-171,088,000-164,368,000-123,180,000-33,743,000-131,217,000-756,870,000-151,520,000-141,435,000-121,446,000-147,866,000-68,239,000-59,948,000-54,772,000-50,134,000

Profile

PhytoHealth Corporation researches and develops, manufactures, and sells pharmaceutical drugs, cosmetics, Class B medicines, and supplementary foods and other related products. Its products include PG2 Lyophilized injection for the treatment of cancer related fatigue; EnerCharge, which is used in enhancing physical strength, maintaining good spirits, and enhancing health maintenance activities; ReyeasCleanse health food capsules; and EnerCharge, an energy drink. The company also offers precision medical equipment and instrument; medical diagnosis software; and computer-aided diagnosis system authorization services. PhytoHealth Corporation was incorporated in 1998 and is based in Taipei, Taiwan.
URL
https://www.phytohealth.com.tw/zh-Hant
IPO date
May 07, 2002
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
153,562
-5.49%
162,489
19.95%
135,465
-19.81%
Cost of revenue
313,743
284,166
292,179
Unusual Expense (Income)
NOPBT
(160,181)
(121,677)
(156,714)
NOPBT Margin
Operating Taxes
312
Tax Rate
NOPAT
(160,181)
(121,677)
(157,026)
Net income
(73,501)
56.00%
(47,117)
-59.04%
(115,035)
47.44%
Dividends
Dividend yield
Proceeds from repurchase of equity
628
1,320
BB yield
-0.02%
-0.03%
Debt
Debt current
6,457
10,542
10,141
Long-term debt
30,223
45,462
50,049
Deferred revenue
Other long-term liabilities
5,011
5,011
5,011
Net debt
(835,928)
(533,767)
(474,640)
Cash flow
Cash from operating activities
(50,134)
(54,772)
(59,948)
CAPEX
(4,715)
(4,730)
(1,605)
Cash from investing activities
(135,137)
26,249
76,920
Cash from financing activities
145,238
(9,177)
(10,522)
FCF
(119,135)
(123,877)
(122,510)
Balance
Cash
1,080,213
1,266,096
1,360,715
Long term investments
(207,605)
(676,325)
(825,885)
Excess cash
864,930
581,647
528,057
Stockholders' equity
2,188,602
2,138,639
2,277,289
Invested Capital
1,526,801
1,722,028
1,784,594
ROIC
ROCE
EV
Common stock shares outstanding
184,600
198,619
198,619
Price
16.80
-22.58%
21.70
13.61%
19.10
-18.03%
Market cap
3,101,280
-28.05%
4,310,032
13.61%
3,793,623
-16.80%
EV
2,732,372
4,119,821
3,688,504
EBITDA
(106,839)
(68,572)
(104,275)
EV/EBITDA
Interest
335
344
312
Interest/NOPBT